Table 1

Patient charateristics and response to treatment

Tumors were staged at presentation using the TMN (6) system by pelvic MRI and after surgery (final stage) by histopathology. Response of the tumor to the primary chemotherapy (Resp. to chemo. column), prior to chemoradiotherapy, is included for reference to the expression profiling data (CR = complete response, PR = partial response, SD = stable disease and PD = progressive disease). Resp. to chemoRT = overall response after completion of chemoradiotherapy. (* = inoperable tumor, # = no operation, R = response and NR = non-response.) LN = lymph node involvement (− = no lymph node involvement, + = lymph node involvement). p53 and Sensc. = immunohistochemical staining for p53 or senescence-associated β-galactosidase (N = negative, P = positive and nd = not done), data from immunoblotting is also included, in brackets, for p53. Ternary complex = presence of inactive ternary complex of TS:FdUMP:5-10 methylenetetrahydrofolate (− = no ternary complex detected, +/− = weak ternary complex signal, + = strong ternary complex signal and nd = not done). Ratios of during treatment expression to pre-treatment expression were calculated for each patient, the number of genes whose expression were increased or decreased >2-fold during treatment are shown for each patient (median = median change >2-fold, Max. = maximum fold change induced treatment.) @ = comparison of 2 pre-treatment biopsies from patient 17 demonstrated that 8 genes fell outside a +/− 2-fold range, median = 2.282, maximum = 5.284.

PTSexAgePresentation stageResp. to chemo.Resp. to chemoRTFinal stageLNOverall resp.P53Senesc.Ternay complexGenes decreasedGenes increased
No.Med.Max.No.Med.Max.
1M59T3SDPRT2RNNnd1220.4320.151422.2366.059
2F56T4SDPDT4NRNNnd1370.4110.164372.8959.550
3F40T3SDSDT3+NRNNnd10.4640.464742.4537.376
4M78RecurrentT0ndndnd850.3990.134183.28411.335
5F53T3PRSDT1RPNnd4630.3490.038902.3428.313
6M60T4PRSDT4*RN (N)N6690.2980.0101362.5546.644
7M61T3CRSDT0Rndndnd4420.3150.0141612.3876.400
8M58T4PDSD#NRN (N)N+350.3860.128132.4985.045
9F69T3PRSDT1+RP (P)N+/−1640.3630.085222.83411.901
10M64T4SDSDT3+NRP (P)N+2750.3490.047162.2374.257
11M30MetastaticPRndndnd1490.3820.067192.38411.426
12M63T3SDPRT3RN (N)N+4480.3470.066612.65715.921
13M56MetastaticPRndNnd1010.4350.2522052.96516.415
14F78T3PRPRT2Rndndnd
15M58MetastaticPRN (P)N+/−4990.3320.0661312.54826.269
16M44T4SDPR#RN (N)N+/−2740.3950.085282.7569.763
17@F61MetastaticSDndndnd1250.4150.17852.1122.493
18M72T3SDSDT1NRP (P)N+4840.2710.0153592.90338.299